

Aggeliki Kolialexi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11566086/publications.pdf>

Version: 2024-02-01

30
papers

712
citations

567281

15
h-index

552781

26
g-index

30
all docs

30
docs citations

30
times ranked

1042
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Hormone Therapy and Flavonoids Capable on Reversal of Menopausal Immune Senescence. <i>Nutrients</i> , 2021, 13, 2363.	4.1	5
2	Known biomarkers for monitoring pregnancy complications. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1-3.	3.1	3
3	Deep Sequencing Identified Dysregulated Circulating MicroRNAs in Late Onset Preeclampsia. <i>In Vivo</i> , 2020, 34, 2317-2324.	1.3	15
4	Quantitative Comparative Proteomics Reveals Candidate Biomarkers for the Early Prediction of Gestational Diabetes Mellitus: A Preliminary Study. <i>In Vivo</i> , 2020, 34, 517-525.	1.3	20
5	<p>Two novel variants in theTCF12 </p>gene identified in cases with craniosynostosis</p>. <i>The Application of Clinical Genetics</i> , 2019, Volume 12, 19-25.	3.0	2
6	Dysregulated placental microRNAs in Early and Late onset Preeclampsia. <i>Placenta</i> , 2018, 61, 24-32.	1.5	49
7	miRNAs in pregnancy-related complications: an update. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 587-589.	3.1	3
8	Plasma biomarkers for the identification of women at risk for early-onset preeclampsia. <i>Expert Review of Proteomics</i> , 2017, 14, 269-276.	3.0	42
9	Proteomics for early prenatal screening of pregnancy complications: a 2017 perspective. <i>Expert Review of Proteomics</i> , 2017, 14, 113-115.	3.0	3
10	Urine proteomic studies in preeclampsia. <i>Proteomics - Clinical Applications</i> , 2015, 9, 501-506.	1.6	16
11	Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia. <i>Disease Markers</i> , 2015, 2015, 1-7.	1.3	11
12	miRNAs in pregnancy-related complications. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 999-1010.	3.1	41
13	Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms. <i>Journal of Hematology and Oncology</i> , 2014, 7, 96.	17.0	36
14	<i>RASSF1A</i> in maternal plasma as a molecular marker of preeclampsia. <i>Prenatal Diagnosis</i> , 2013, 33, 682-687.	2.3	42
15	Early non-invasive detection of fetal Y chromosome sequences in maternal plasma using multiplex PCR. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012, 161, 34-37.	1.1	28
16	Proteomic analysis of amniotic fluid for the diagnosis of fetal aneuploidies. <i>Expert Review of Proteomics</i> , 2011, 8, 175-185.	3.0	14
17	Application of proteomics for the identification of biomarkers in amniotic fluid: are we ready to provide a reliable prediction?. <i>EPMA Journal</i> , 2011, 2, 149-155.	6.1	11
18	Biomarker development for non-invasive prenatal diagnosis of fetal aneuploidies: predictive reliability and potential clinical application. <i>EPMA Journal</i> , 2011, 2, 157-161.	6.1	0

#	ARTICLE	IF	CITATIONS
19	Non-invasive prenatal diagnosis using cell-free fetal nucleic acids in maternal plasma: Progress overview beyond predictive and personalized diagnosis. EPMA Journal, 2011, 2, 163-171.	6.1	19
20	A multiplex PCR for non-invasive fetal RHD genotyping using cell-free fetal DNA. In Vivo, 2011, 25, 411-7.	1.3	12
21	Proteomic analysis of amniotic fluid in pregnancies with Klinefelter syndrome foetuses. Journal of Proteomics, 2010, 73, 943-950.	2.4	34
22	Potential Biomarkers for Turner in Maternal Plasma: Possibility for Noninvasive Prenatal Diagnosis. Journal of Proteome Research, 2010, 9, 5164-5170.	3.7	23
23	Noninvasive fetal RhD genotyping from maternal blood. Expert Review of Molecular Diagnostics, 2010, 10, 285-296.	3.1	13
24	Application of proteomics for diagnosis of fetal aneuploidies and pregnancy complications. Journal of Proteomics, 2009, 72, 731-739.	2.4	13
25	Proteomics in prenatal diagnosis. Expert Review of Proteomics, 2009, 6, 111-113.	3.0	9
26	Application of proteomics for the identification of differentially expressed protein markers for Down syndrome in maternal plasma. Prenatal Diagnosis, 2008, 28, 691-698.	2.3	60
27	Mass spectrometry-based proteomics in reproductive medicine. Mass Spectrometry Reviews, 2008, 27, 624-634.	5.4	53
28	Proteomic Analysis of Amniotic Fluid in Pregnancies with Turner Syndrome Fetuses. Journal of Proteome Research, 2008, 7, 1862-1866.	3.7	33
29	Proteomic analysis of human reproductive fluids. Proteomics - Clinical Applications, 2007, 1, 853-860.	1.6	8
30	Proteomic analysis of amniotic fluid in pregnancies with Down syndrome. Proteomics, 2006, 6, 4410-4419.	2.2	94